The NCI COVID-19 in Cancer Patients Study, or NCCAPS, is a natural history study of COVID-19 in people with cancer. In a natural history study, researchers follow people and collect medical and other information about them over time to learn more about how a disease and its symptoms develop and change. Diagnosis and treatment of a disease are not part of natural history studies. The knowledge gained through this study will help doctors better manage treatment for people with cancer and COVID-19 in the future. The Principal Investigators of this study are Dr. Beth Y. Karlan and Dr. Gottfrield Konecny.
For more information >
The UCLA OBGYN physicians are nationally and internationally recognized not only for their clinical expertise but also for their pioneering research. Our goal is to increase basic research and translate the findings into clinical trials.
What is a clinical trial? A clinical trial is a study conducted with actual patients, usually to evaluate a new treatment. Each study is designed to answer scientific questions and to find new and better ways to help our patients.
Cancer - Ovarian, Fallopian Tube and Peritoneal Cancer
Recurrent Ovarian Cancer: GOG 3045: IMGN853-0416: MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. chemo in Platinum-Resistant, Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
Recurrent Ovarian Cancer: GOG 3059: A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer
Cancer - Uterine and Endometrial
Advanced or Metastatic Endometrial Cancer: GOG 3038: A Multicenter, Open-label, Nonrandomized, Phase 2 Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)
Cancer - Cervical
Women at High Risk for Ovarian and Breast Cancers
Benign / Non-Cancer
PRIORITY (Pregnancy CoRonavirus Outcomes RegIsTrY) is a nationwide study of pregnant or recently pregnant women who are either under investigation for Coronavirus infection (COVID-19) or have been confirmed to have COVID-19. Yalda Afshar, MD, PhD, a UCLA OBGYN maternal fetal medicine specialist, is a CO-PI on this study that is overseen by a team from UCSF and which is being done to help patients and doctors better understand how COVID-19 impacts pregnant women and their newborns. For more information > | Study flyer >
For more information about clinical trials at UCLA Obstetrics and Gynecology, please contact:
Jenny Lester, MPH, CCRP
Director of Clinical Trials
Obstetrics and Gynecology, David Geffen School of Medicine at UCLA
Email: [email protected]
Clinical Trial Resources: